Please assess the completion status of the following clinical trial:

Trial Title: Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Is a male or female at least 18 years old~* Has relapsed or refractory MM and has had at least one prior therapy~* Female participants of childbearing potential must have 2 negative serum pregnancy tests prior to receiving the first dose of study drugs~* Female participants who can become pregnant must agree to use 2 separate forms of effective birth control at the same time, 4 weeks before, while taking, and for 4 weeks after stopping lenalidomide; post menopausal participants should be free from menses for \>2 years, or are surgically sterilized~* Male participant agrees to use an adequate method of contraception for the duration of the study, even if the participant has undergone a successful vasectomy~* Male participants must agree to use a latex condom during sexual contact with a pregnant female or a female who can become pregnant; this is required for the duration of the study, and for 4 weeks after stopping therapy~* Has at least 3 weeks washout prior to treatment~* Is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis~Exclusion Criteria:~* Has prior treatment with a histone deacetylase (HDAC) inhibitor~* Has prior allogenetic bone marrow transplant~* Has received intravenous antibiotics, antiviral, or antifungal agents within 2 weeks prior to the start of the study drug~* Uses illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse~* Is pregnant or breast feeding or expecting to have a baby during the course of the study~* Has human immunodeficiency virus (HIV) infection~* Has Hepatitis B/C infection~* Is currently receiving treatment for another type of cancer other than skin or cervical cancer that has not been in remission for 5 years or longer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Level 1: Vorinostat 300 mg + lenalidomide 10 mg (Type: EXPERIMENTAL): Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
- Level 2: Vorinostat 400 mg + lenalidomide 10 mg (Type: EXPERIMENTAL): Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
- Level 3: Vorinostat 400 mg + lenalidomide 15 mg (Type: EXPERIMENTAL): Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
- Level 4: Vorinostat 400 mg + lenalidomide 20 mg (Type: EXPERIMENTAL): Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
- Level 5: Vorinostat 400 mg + lenalidomide 25 mg (Type: EXPERIMENTAL): Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).